Ramucirumab and paclitaxel in platin refractory advanced or metastatic gastric or gastrooesophageal junction adenocarcinoma – a single center exper...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter U. Vogl
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors U. Vogl1, L. Vormittag1, T. Winkler2, A. Kafka1, O. Weiser-Jasch3, H. Andalibi3, W. Schima4, A. Klaus5, J. Zacherl6, L. Öhler1
  • 1St. Josef Hospital Vienna, Medicine I, Oncology, Vienna, Austria, /
  • 2St. Josef Hospital Vienna, Vienna, Austria, /
  • 3St. Josef Hospital Vienna, Vienna, Vienna, /
  • 4St. Josef Hospital Vienna, Department of Radiology, Vienna, Austria, /
  • 5Krankenhaus Barmherzige Schwestern Vienna, Department of Surgery, Vienna, Austria, /
  • 6St. Josef Hospital Vienna, Department of Surgery, Vienna, Austria, /

Abstract

Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data of 20 patients treated with Ramucirumab and Paclitaxel after failure of at least one platinum and 5-FU-containing chemotherapy regimen at our center.